China Health Management Corp.

China Health Management Corp. operates as a healthcare and management company in China. It focuses on the operation and management of hospitals. The company provides healthcare services in the areas of gynaecology and obstetrics, paediatrics, stomatology, dermatology, medical cosmetology, pathology, ophthalmology and otolaryngology, anesthesia, and haemodialysis. Its services also include surgery, emergency medicine, intensive care, preventive medicine, pharmacy, psychological consultation therapy, medical consultation, combined Chinese and Western medicine, medical examination, medical imaging, medical functions examination, commissioning hospital management, hospital management consultation, etc. The company was formerly known as Max Internet Communications, Inc. and changed its name to China Health Management Corp. in March 2006. China Health Management Corp. was incorporated in 1996 and is based in Dallas, Texas.

China Health Management Corp. trades as CNHC on OTC. The company is classified in Financial Services / Shell Companies and reports in USD.

The current profile places the business in Shell Companies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $52,651 of revenue and -$7,934 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

China Health Management Corp. can be compared against peers such as All American Pet Company, Inc., BioCube, Inc., China Dongsheng International, Inc., First Colombia Gold Corp., Jade Art Group Inc., Myrexis, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $284,011, beta of -1.36, and return on equity of +3.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CNHC currently shows total debt of $465,821 and beta of -1.36. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.chinahealthcorp.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.